Vivoryon Therapeutics N.V. will report its full year 2023 financial results and operational progress on April 24, 2024. Vivoryon is a clinical-stage company focused on discovering and developing small molecule medicines to modulate the activity and stability of pathologically altered proteins. The company will host a conference call and webcast that is open to the public. The report will be available for download on the Company’s website. Conference call details include a date of April 24, 2024 and time of 3:00 pm CEST / 9:00 am EDT. The conference call can be accessed via phone and webcast. The live audio webcast of the call will be available on Vivoryon ́s website at a specific link. To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via a website link. It is suggested participants dial into the conference call 15 minutes prior to the scheduled start time to avoid any delays in attendance. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by a passion for ground-breaking science and innovation, the company strives to change the lives of patients suffering from severe diseases. Expertise in understanding post-translational modifications is leveraged to develop medicines that modulate the activity and stability of proteins altered in disease. Beyond the lead varoglutamstat program in Phase 2 for Alzheimer’s disease, a solid pipeline of orally available small molecule inhibitors has been established for various indications including cancer, inflammatory diseases and fibrosis. The company website provides additional information. This press release includes forward-looking statements regarding estimates, projections, forecasts and statements as to when products may be available. These forward-looking statements involve known and unknown risks and uncertainties that could materially adversely affect outcomes and effects. Actual results, performance or events may differ from those expressed or implied. As a result, no undue reliance should be placed on such forward-looking statements. Risk factors that may affect future financial results are discussed in published annual financial statements. This press release speaks as of the date and the company assumes no obligation to update, save for legally required disclosures. Investor and media contact details are provided.